secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001104659-24-120165
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist announces positive Phase 3 results for icotrokinra; earns $165M milestone
--------------------------------------------------------------------------------

- ICONIC-LEAD met co-primary endpoints: 64.7% achieved IGA 0/1, 49.6% PASI 90 at week 16 vs placebo 8.3% and 4.4%.
- ICONIC-TOTAL met primary endpoint of IGA 0/1 at week 16; results in difficult-to-treat areas.
- Earned $165M milestone under amended collaboration with Janssen; payment expected Q1 2025.
- Company remains eligible for up to $630M in future milestones and tiered royalties of 6-10% on net sales.
- Upcoming catalysts H1 2025: Phase 2b ulcerative colitis data, PsA Phase 3 start, superiority data vs deucravacitinib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924120165/0001104659-24-120165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924120165/tm2428765d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-120165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer